Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311879 | 0.94 | TLR2 (0.54) | TLR2KMT2ATPSAB1 | |
| SCHEMBL13311882 | 0.94 | TLR2 (0.54) | TLR2KMT2ATPSAB1 | |
| SCHEMBL12019008 | 0.92 | TLR2 (0.49) | TLR2KMT2ATPSAB1MDM2 | |
| SCHEMBL12040119 | 0.90 | MDM2 (0.54) | TLR2KMT2AMDM2 | |
| SCHEMBL13938802 | 0.89 | KMT2A (0.59) | TLR2KMT2ATPSAB1MDM2 | |
| SCHEMBL27407607 | 0.85 | TLR2 (0.57) | TLR2MDM2 | |
| SCHEMBL16592017 | 0.85 | KMT2A (0.58) | TLR2KMT2ATPSAB1MDM2 | |
| SCHEMBL16093051 | 0.85 | KMT2A (0.50) | TLR2KMT2AMDM2 | |
| SCHEMBL10078346 | 0.85 | KMT2A (0.50) | TLR2KMT2AMDM2 | |
| SCHEMBL13311876 | 0.84 | TLR2 (0.61) | TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309514-B2 | Peptide nucleic acid based guanidinium compounds | NITTO DENKO CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100160239-A1 | PEPTIDE NUCLEIC ACID BASED GUANIDINIUM COMPOUNDS | NITTO DENKO CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-7700565-B2 | Peptide nucleic acid based guanidinium compounds | NITTO DENKO CORPORATION (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20070072802-A1 | Peptide nucleic acid based guanidinium compounds | NITTO DENKO CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072802-A1 | Peptide nucleic acid based guanidinium compounds | SLC29A1, SLC29A2, SLC28A1 | TLR2 1447/4885KMT2A 4167/4885TPSAB1 4447/4885 |
| US-20100160239-A1 | PEPTIDE NUCLEIC ACID BASED GUANIDINIUM COMPOUNDS | SLC29A1, SLC29A2, SLC28A1 | TLR2 1881/4885KMT2A 4006/4885TPSAB1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.